rifampin and Bursitis

rifampin has been researched along with Bursitis* in 4 studies

Reviews

2 review(s) available for rifampin and Bursitis

ArticleYear
Rare form of brucellosis, subacromial and subdeltoid bursitis: A case report and literature review.
    Eklem hastaliklari ve cerrahisi = Joint diseases & related surgery, 2019, Volume: 30, Issue:3

    Brucellosis is a zoonosis seen all over the world and is still endemic in certain parts of the world. Brucellosis is a systemic infection which involves multiple organs and tissues. Although musculoskeletal system involvement is frequent in brucellosis, bursal involvement is seen rarely. In this article, we present a case of subacromial and subdeltoid brucellar bursitis with positive serology and aspiration culture. Patient achieved complete recovery with rifampicin and doxycycline treatment, without any evidence of relapse. A high clinical suspicion is required for the diagnosis of brucellar bursitis.

    Topics: Aged; Anti-Bacterial Agents; Brucellosis; Bursitis; Diagnosis, Differential; Doxycycline; Drug Therapy, Combination; Humans; Male; Rifampin; Shoulder Joint

2019
Brucellosis as a rare cause of olecranon bursitis: case-based review.
    Rheumatology international, 2019, Volume: 39, Issue:12

    A 51-year-old man shepherd presented with mild pain and swelling of the right posterior aspect of his right elbow. In ultrasonography, the affected bursal space had swelling and effusion. Moreover, the aspiration of the affected bursa revealed an inflammatory profile. Brucella melitensis was detected in aspirated fluid and blood cultures. The serum agglutination test (SAT) and 2-mercaptoethanol test for brucellosis were also positive. Therefore, the diagnosis of brucellar olecranon was confirmed. Treatment was initiated using gentamicin for the first 7 days and doxycycline plus rifampicin for 2 months. After treatment, all clinical signs and symptoms were resolved. No relapse was seen after 1 year of the completion of treatment. Clinicians should pay attention to the symptoms of olecranon brucellar bursitis that is similar to that of pyogenic bursitis.

    Topics: Anti-Bacterial Agents; Brucella melitensis; Brucellosis; Bursitis; Doxycycline; Drug Therapy, Combination; Gentamicins; Humans; Male; Middle Aged; Olecranon Process; Rifampin; Treatment Outcome; Ultrasonography

2019

Other Studies

2 other study(ies) available for rifampin and Bursitis

ArticleYear
Olecranon bursitis secondary to Mycobacterium kansasii infection in a patient receiving infliximab for Behcet's disease.
    Journal of medical microbiology, 2009, Volume: 58, Issue:Pt 3

    We present a case of Mycobacterium kansasii olecranon bursitis in a woman with known immunosuppression secondary to the treatment received for her Behçet's disease. We found only one other case report of olecranon bursitis caused by M. kansasii in the literature, which, unlike our case, presented in an immunocompetent adult following trauma. This case extends the range of opportunistic mycobacterial infections that are associated with anti-tumour necrosis factor therapy.

    Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antitubercular Agents; Behcet Syndrome; Bursitis; Elbow; Ethambutol; Female; Humans; Immunocompromised Host; Infliximab; Middle Aged; Mycobacterium Infections, Nontuberculous; Mycobacterium kansasii; Rifampin

2009
Cloxacillin-based therapy in severe septic bursitis: retrospective study of 82 cases.
    Joint bone spine, 2009, Volume: 76, Issue:6

    The purpose of this retrospective study was to describe a tertiary care center experience with different antibiotic strategies that include cloxacillin (C) in patients with severe septic bursitis (SB).. A severe SB was considered when the patient needed hospitalization and/or intravenous (i.v.) antibiotics. Patients were treated with bursal aspiration and one of these antibiotic options: C, 2 g/4 h per day i.v. until improvement, and afterwards 1 g/6 h per day v.o. until resolution; (C+G), gentamicin i.v. was added to C for 5 to 7 days (initial dose 240 mg/d); (C+R), rifampicin was added at a dose of 600 mg/d v.o.. The study comprised 82 patients with severe SB. The mean delay to diagnosis was 6.1+/-6.9 days, and the most frequent location was the prepatellar bursa. In 67%, the bursal fluid culture yield a positive result, being Staphylococcus aureus the most frequent bacteria isolated (94.4%). At admission, fever and extensive cellulites were more frequent in the C+G group. Patients in the C+G had a longer duration of i.v. antibiotics compared with the C group (p=0.008), although the total duration of antibiotics was not different. There was a tendency in the C+R group to need more surgery. All patients except one had a complete resolution and there were no differences in side effects.. In patients with severe SB without extensive cellulites i.v., C alone may be sufficient. In patients with a more severe presentation, C plus gentamicin seems to be an appropriate option in the majority of them.

    Topics: Anti-Bacterial Agents; Bursa, Synovial; Bursitis; Cloxacillin; Drug Therapy, Combination; Elbow Joint; Female; Gentamicins; Hospitals, University; Humans; Injections, Intravenous; Knee Joint; Male; Middle Aged; Retrospective Studies; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome

2009